Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or...
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE®...
Emittent / Herausgeber: CLINUVEL PHARMACEUTICALS LTD / Schlagwort(e): Sonstiges Biotech-Unternehmen CLINUVEL launcht Photomedizin-Stiftung bei Event von Lady Gaga 07.03.2024 / 09:00 CET/CEST...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level...
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE®...
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet...
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the...
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug...
ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -0.0552181115406 | 9.055 | 9.44 | 8.8 | 4535 | 9.01791419 | DE |
| 4 | 0.775 | 9.36555891239 | 8.275 | 9.6649999 | 7.905 | 5117 | 8.90820532 | DE |
| 12 | -0.38 | -4.02969247084 | 9.43 | 10.79 | 7.905 | 4598 | 9.13184173 | DE |
| 26 | 0.5520001 | 6.49564728755 | 8.4979999 | 10.79 | 7.905 | 5191 | 9.14144352 | DE |
| 52 | -0.8039999 | -8.15912226668 | 9.8539999 | 11.095 | 7.905 | 5753 | 9.27566461 | DE |
| 156 | -2.145 | -19.1603394372 | 11.195 | 11.395 | 7.905 | 5903 | 9.35000125 | DE |
| 260 | -2.145 | -19.1603394372 | 11.195 | 11.395 | 7.905 | 5903 | 9.35000125 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
